+++
author = ""
title = "Diabetes and PVD"
date = "2019-10-29"
description = "Diabetes and PVD Lecture"
tags = ["Masters", "Fundamentals of Prosthetics and Orthotics"]
categories = ["Masters", "Fundamentals of Prosthetics and Orthotics"]
series = ["University Journal"]
aliases = ["migrate-from-jekyl"]
+++

<font size="+7" color="orange"><center> Introduction </center></font>  
---

Prevalence:

- 4.8 Million UK pop.
- 5 Million by 2025

Issue:

- Glucose management issue

Types:

- Type 1: Genetic
- Type 2: Bad diet and lack of exercise
- Other

---

<br><br>

<font size="+7" color="orange"><center> Body Vascular Anatomy </center></font>  
---

{{<figure src="/PVD/Anatomy.jpg" position="center" style="border-radius: 8px;" caption="Body Vascular Anatomy" captionPosition="center" captionStyle="color: white;" >}}

---

<br><br>

<font size="+7" color="orange"><center> Foot Vascular Anatomy </center></font>  
---

{{<figure src="/PVD/Foot.jpg" position="center" style="border-radius: 8px;" caption="Foot Vascular Anatomy" captionPosition="center" captionStyle="color: white;" >}}

---

<br><br>

<font size="+7" color="orange"><center> Diabetes Mellitus </center></font>  
---

{{<figure src="/PVD/Diabetes.jpg" position="center" style="border-radius: 8px;" caption="Diabetes Mellitus Flowchart" captionPosition="center" captionStyle="color: white;" >}}

---

<br><br>

<font size="+7" color="orange"><center> Diabetes Neuropathy </center></font>  
---

- Neuropathy = nerve damage

- NCS = nerve conduction

- Vibration, Pressure/Touch and Motor/Reflex are the most common tests

{{<figure src="/PVD/Neuropathy.JPG" position="center" style="border-radius: 8px;" caption="Diabetes Neuropathy" captionPosition="center" captionStyle="color: white;" >}}

---

<br><br>

<font size="+7" color="orange"><center> PVD </center></font>  
---

- What is PVD?
    - Arterial
    - Venous
    - Lymphatic
    - Peripheral Arterial Disease (PAD)
    - Intermittent Claudication
    - Critical Limb Ischaemia
    - Gangrene

{{<figure src="/PVD/Veins.JPG" position="center" style="border-radius: 8px;" caption="What is PVD?" captionPosition="center" captionStyle="color: white;" >}}

{{<figure src="/PVD/Vein2.JPG" position="center" style="border-radius: 8px;" caption="Progressive Luminal Occlusion?" captionPosition="center" captionStyle="color: white;" >}}

{{<figure src="/PVD/Cycle.JPG" position="center" style="border-radius: 8px;" caption="Transfer of Glucose in the Body" captionPosition="center" captionStyle="color: white;" >}}

### **<mark>Effects of PVD<mark>**
- Pain
- Callus
- Numbness
- Deformity
- Ulcers
- Gangrene
- Neuropathy (nerve damage)
- Ischemia (reduced blood supply)

---

<br><br>

<font size="+7" color="orange"><center> Diagnosis </center></font>  
---

### **<mark>Signs and Symptoms<mark>**
- Intermittent Claudication
- Rest Pain
- Numbed/dull leg

<font size="+4" color="orange"><center> Method 1: Pedal Pulse Palpitation </center></font>  

- Regularity
- Symmetry
- Strength
- *Is this subjective?*

---

<br><br>

<font size="+4" color="orange"><center> Method 2: Doppler Ultrasound </center></font>  

- Regularity
- Symmetry
- Strength
- *Is this objective?*

{{<figure src="/PVD/Doppler.JPG" position="center" style="border-radius: 8px;" caption="Doppler Ultrasound: How it works" captionPosition="center" captionStyle="color: white;" >}}

### **<mark>Doppler Ultrasound Probe Positioning<mark>**
{{<figure src="/PVD/Position1.JPG" position="center" style="border-radius: 8px;" caption="Doppler Ultrasound: Where to Position the Probe" captionPosition="center" captionStyle="color: white;" >}}

### **<mark>Which Pulses should be assessed<mark>**
-  All guidelines concur that at least 2 pulses should be assessed for each foot.
- Normally these are: 
    - posterior tibial,
    - dorsalis pedis
    - anterior tibial.

- However, NICE guidance recommends that they should always include the peroneal pulse as this may be the only one present in some people, particularly those with diabetes (NICE, 2012).

{{<figure src="/PVD/Position2.JPG" position="center" style="border-radius: 8px;" caption="Arteries of the Foot" captionPosition="center" captionStyle="color: white;" >}}

---

<br><br>

<font size="+4" color="orange"><center> Method 3: ABPI </center></font>  


### **<mark>Ankle-brachial Pressure Index (ABPI) Calculation<mark>**

{{<figure src="/PVD/ABI.JPG" position="center" style="border-radius: 8px;" caption="ABI Calculation" captionPosition="center" captionStyle="color: white;" >}}

### **<mark>ABPI Interpretation<mark>**

| ABPI      	| Diagnosis      	|
|-----------	|----------------	|
| < 0.5     	| Severe PAD     	|
| 0.5 - 0.7 	| Moderate PAD   	|
| 0.7 - 0.9 	| Mild PAD       	|
| 0.9 - 1.3 	| Normal         	|
| > 1.3     	| Calcification? 	|


### **<mark>ABPI in Diabetes<mark>**

{{<figure src="/PVD/ABI2.JPG" position="center" style="border-radius: 8px;" caption="ABI in Diabetes" captionPosition="center" captionStyle="color: white;" >}}

---

<br><br>

<font size="+4" color="orange"><center> Method 4: Toe Pressure </center></font>  

- Regularity
- Symmetry
- Strength
- *Is this objective?*

### **<mark>Toe Brachial Index (TBI)<mark>**

- TBI > 0.7 = normal

- Rest pain
    - often in patients with TBI < 0.15
    - absolute pressure in the toes of 20-30 mmHg

---

<br><br>

<font size="+4" color="orange"><center> Method 5: Transcutaneous Oxygen </center></font> 

- Microcirculation
- Very localised
- TcPO2 > 50 mmHg = normal
- Determine Amputation Level
- Determine Healing Potential
    - Poor chances if <30mmHG

{{<figure src="/PVD/TO.JPG" position="center" style="border-radius: 8px;" caption="Transcutaneous Oxygen" captionPosition="center" captionStyle="color: white;" >}}

---

<br><br>

<font size="+4" color="orange"><center> Diagnosis - Gold Standard Transcutaneous Oxygen </center></font> 

### **<mark>Arterial Duplex<mark>**
- Regularity
- Symmetry
- Strength
- *Is this objective?*

### **<mark>CT Angiography<mark>**
- Regularity
- Symmetry
- Strength
- *Is this objective?*

### **<mark>Toe Brachial Index (TBI)<mark>**
- Regularity
- Symmetry
- Strength
- *Is this objective?*

---

<br><br>

<font size="+7" color="orange"><center> NHS Integrated Care Pathway </center></font> 
---

{{<figure src="/PVD/PAD_path.JPG" position="center" style="border-radius: 8px;" caption="PAD Integrated Care Pathway" captionPosition="center" captionStyle="color: white;" >}}

### **<mark>Referral Pathway<mark>**

{{<figure src="/PVD/Referral.JPG" position="center" style="border-radius: 8px;" caption="NHS Urgent Referral Pathway" captionPosition="center" captionStyle="color: white;" >}}

---

<br><br>

<font size="+7" color="orange"><center> Treatments for PVDS </center></font> 
---

|           	| Conservative                                            	| Medical                                                                                                                         	| Surgical          	|
|-----------	|---------------------------------------------------------	|---------------------------------------------------------------------------------------------------------------------------------	|-------------------	|
| Method    	| Exercise                                                	| Peripheral Vasodilators                                                                                                         	| Angioplasty/Stent 	|
| Treatment 	| Managing your risk factors                              	| Anti-Platelet medication, Statins                                                                                               	| Bypass            	|
| Details   	| - High BP - Smoking Cessation - Diet - Diabetes Control 	| - cilostazol, nifedipine, naftidrofuryl oxalate (vasodilators) - aspirin or clopidogrel (antiplatelet) - Art/Rosuv/Simv STATINS 	|                   	|

---

<br><br>

<font size="+7" color="orange"><center> Critical Limb Ischemia (CLI) </center></font> 
---

Only method of treatment is **amputation**
- feet are black
- muscle death due to lack of blood supply

---

<br><br>

<font size="+7" color="orange"><center> P & 0 Consideration </center></font> 
---

- Materials
- Aims and Objectives
    - Short term
    - Long term

---

<br><br>

<font size="+7" color="orange"><center> References </center></font> 
---

1. Soyoye, D. O., Ikem, R. T., Kolawole, B. A., Oluwadiya, K. S., Bolarinwa, R. A., & Adebayo, O. J. (2016). Prevalence and Correlates of Peripheral Arterial Disease in Nigerians with Type 2 Diabetes. Adv Med, 2016, 3529419. https://doi.org/10.1155/2016/3529419

2. Wang, Z., Wang, X., Hao, G., Chen, Z., Zhang, L., Shao, L.,… China hypertension survey, investigators. (2019). A national study of the prevalence and risk factors associated with peripheral arterial disease from China: The China Hypertension Survey, 2012-2015. Int J Cardiol, 275, 165–170. https://doi.org/10.1016/j.ijcard.2018.10.047

3. Pradeepa, R., Chella, S., Surendar, J., Indulekha, K., Anjana, R. M., & Mohan, V. (2014). Prevalence of peripheral vascular disease and its association with carotid intima-media thickness and arterial stiffness in type 2 diabetes: the Chennai urban rural epidemiology study (CURES 111). Diab Vasc Dis Res, 11(3), 190–200.
https://doi.org/10.1177/1479164114524584

4. Felício, J. S., Koury, C. C., Abdallah Zahalan, N., de Souza Resende, F., Nascimento de Lemos, M., Jardim da Motta Corrêa Pinto, R., … Abrahão Neto, J. F. (2019). Ankle-brachial index and peripheral arterial disease: An evaluation including a type 2 diabetes mellitus drug-naive patients cohort. Diab Vasc Dis Res, 1479164119829385. https://doi.org/10.1177/1479164119829385

5. Urbano, L., Portilla, E., Munoz, W., Hofman, A., Sierra-Torres, C. H., Muñoz, W., … Sierra-Torres, C. H. (2018). Prevalence and risk factors associated with peripheral arterial disease in an adult population from Colombia. Arch Cardiol Mex, 88(2), 107–115. https://doi.org/10.1016/j.acmx.2017.02.002

6. Okello, S., Millard, A., Owori, R., Asiimwe, S. B., Siedner, M. J., Rwebembera, J., … Annex, B. H. (2014). Prevalence of lower extremity peripheral artery disease among adult diabetes patients in southwestern Uganda. BMC Cardiovasc Disord 14 75 https://doi org/10 1186/1471-2261-14-75